Global Rx Medical Food Market, by Product type (Pills, Powder, Liquid, and Others (Wafers, Chewable, and Bars)), by Therapeutic Application (Pain Management, Sleep Disorder, Neurological Disorder, Gastrointestinal Disorder, Pulmonary Disorders, Metabolic Disorders, and Others (Fibrosis, Dialysis, AIDS, and Others)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Supermarkets), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was estimated to be valued at US$ 17,219.8 million in 2019, and is expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027).
Growing regulatory support, increasing awareness about medical food in emerging economies, and advantages over drug therapies are expected to be the major factors driving growth of the global Rx medical food market over the forecast period.
Manufacturers are focused on developing medical food products with improved therapeutic effects and different dosage forms for ease of administration and patient convenience. For instance, Abbott laboratories launched science-based nutrition drinks such as Ensure Surgery Immunonutrition Shake and Ensure Pre Surgery Clear Nutrition in 2016, it is designed to support immune health, reduces insulin resistance and fastens surgery recovery time.
Moreover, in 2017, Cera Products, Inc. launched Ceralyte oral rehydration salt to treat dehydration and diarrhea. Furthermore, in 2017, Cambrooke launched Tylacti COMPLETE Bars, a nutritionally complete medical food available for dietary management of Tyrosinemia (TYR). Cambrooke also launched medical food line Phenactin AA Plus, Vilactin AA Plus, Isovactin AA Plus, Homactin AA Plus, and Promactin AA Plus for inborn errors of metabolism in 2015. Furthermore, Nutricia Metabolics launched Anamix Next for Tyrosinemia, Methylmalonic Acidemia, and Isovaleric Acidemia in 2015. Moreover, Nutricia Metabolics launched PhenylAde GMP, a new formula for Phenylketonuria (PKU) in 2015.
Key players are investing in research and development activities of pipeline products for the development of novel medical food that can be used in various medical conditions. For instance, in 2012, Targeted Medical Pharma reported preliminary data of its new amino acid-based oral formulation called PERCURA, which can be used for reducing symptoms of pain and numbness associated with peripheral neuropathy, in an open-label pilot study. Moreover, in 2015, Enzymotec Ltd announced investigator initiated clinical trial of Vayarin, which is capable of managing attention deficit hyperactivity disorder (ADHD) in children suffering from epilepsy. Moreover, scientists at Nestlé Institute of Health Science are studying human DNA for the development of personalized programs for epilepsy and intestinal disorders, thereby leading to development of medical food products that contain natural compounds.
Browse 40 Market Data Tables and 35 Figures spread through 166 Pages and in-depth TOC on Rx Medical Food market, by Product type (Pills, Powder, Liquid, and Others (Wafers, Chewable, and Bars)), by Therapeutic Application (Pain Management, Sleep Disorder, Neurological Disorder, Gastrointestinal Disorder, Pulmonary Disorders, Metabolic Disorders, and Others (Fibrosis, Dialysis, AIDS, and Others)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Supermarkets), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"
To know the latest trends and insights related to immune repertoire sequencing market, click the link below:
Major players are adopting strategies such as mergers and acquisitions to expand their product portfolio and enter into the medical food industry. For instance, Nestlé is adding medical foods such as prescription-based powders and drinks that can be used for treatment of diseases to its existing product portfolio for business expansion, which, in turn, will help the company to enter the nutrition sector. Moreover, in 2017, AlfaSigma, an Italy-based company completed the acquisition of the U.S. medical food maker Pamlab from Nestlé, to strengthen the company’s operations in North America. Furthermore, the U.S. Food & Drug Administration (FDA) award grants every year in September and October through the Orphan Products Clinical Trials Grants Program, to fund and encourage clinical trials for development of medical products, which includes drugs, medical food to treat rare diseases or conditions.
Key Takeaways of the Immune Repertoire Sequencing Market:
Major players operating in the Rx medical food market include Abbott Laboratories, Danone S.A., Mead Johnson & Company, LLC, Fresenius Kabi AG, Nestle S.A., Primus Pharmaceuticals, Inc., Targeted Medical Pharma, Enzymotec ltd., AlfaSigma, and Pivotal Therapeutics.
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.